HB1809 Establishing a medical psilocybin advisory board to assess the advantages and disadvantages of the use of psilocybin for therapeutic purposes.
Establishing a medical psilocybin advisory board to assess the advantages and disadvantages of the use of psilocybin for therapeutic purposes.
Impact Score — How Does This Bill Affect You?
Overall Impact Score
Mixed
Scale: 1 (harmful) to 10 (beneficial)
Your Wallet
Advisory board has minimal cost; findings could lead to cost-effective treatments for mental health conditions.
Your Community
A careful, evidence-based approach to evaluating psilocybin therapy could benefit NH's mental health crisis.
Your Freedom
Opens the door to expanded treatment options through responsible scientific evaluation.
Status
Inexpedient to Legislate, Motion Adopted, Voice Vote === BILL KILLED ===; 05/07/2026; Senate Journal 11
Sponsor
Buzz Scherr (D)
The Short Version
Creates an advisory board to study the therapeutic use of psilocybin, a more cautious approach than directly legalizing clinical use. Advancing through Senate Health committee.
Who's Behind This Bill?
Who Benefits
- ▲ Mental health patients awaiting new treatment options
- ▲ Researchers studying psilocybin therapy
- ▲ Evidence-based policymaking
Who Pays the Price
- ▼ Minimal; advisory board operating costs
Bill statuses as of May 2026. Check LegiScan or NH General Court for the latest.
This bill was auto-scored using AI analysis of the bill text and legislative data. Scores may be refined as we review more bills.